Chad E. Beyer, Ph.D., MBA Corporate Faculty (BTMS)

Chad E. Beyer, PhD, MBA is Senior Vice President of Research and Development (R&D) at Promentis Pharmaceuticals and has over 20 years of experience in the research, discovery and development of medications aimed to treat disorders of the brain and central nervous system. Prior to joining Promentis, Dr. Beyer was the Head of R&D at Ariel Pharmaceuticals and Head of Neurochemistry at Wyeth Pharmaceuticals. During his career, Dr. Beyer led several early-stage clinical drug discovery teams, participated in the submission of more than 30 INDs and managed a group responsible for contributing to the commercialization and life-cycle management of two blockbuster medications: Effexor® and Pristiq®. Dr. Beyer holds a Ph.D. in Neuropharmacology from LSU Medical Center and an MBA from the Rutgers Business School. Notably, Dr. Beyer has help raise more than $30M of equity investment, authored more than 70 manuscripts, co-edited a book entitled “Next Generation Antidepressants” and co-founded the journal “Technology Transfer & Entrepreneurship.” Dr. Beyer was an adjunct faculty member at Thomas Jefferson University and is now a Corporate faculty member at Harrisburg University where he teaches “Improvisation and R&D”, a course focused on exploring doing ‘the Business of Science.’